NEW YORK (GenomeWeb News) – Horizon Discovery said today it has inked a worldwide distribution deal covering Haplogen's haploid cellular models.

Under the terms of the deal, effective immediately, customers will be able to purchase directly from Horizon, Haplogen's Haploid Gene Trap Mutant Collection of isogenic human cell lines deficient for the expression of single genes. Horizon said the deal is its first covering the distribution of another company's products.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.